Medtronic plc (MDT) FY2024 Annual P&L / Income Statement

Medtronic plc (MDT) FY2024 Annual P&L / Income Statement

Income statement for 2023-04-29 through 2024-04-26. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

32,364,000,000 US dollars

Cost of products sold, excluding amortization of intangible assets

11,216,000,000 US dollars

Gross profit (calculated)

21,148,000,000 US dollars

Operating costs, including other operating expenses (calculated)

16,003,000,000 US dollars

Operating profit

5,144,000,000 US dollars

Other income (expense), net (calculated)

negative 307,000,000 US dollars

Income before income taxes

4,837,000,000 US dollars

Income tax provision

1,133,000,000 US dollars

Net income

3,705,000,000 US dollars

Cardiovascular

11,831,000,000 US dollars

Neuroscience

9,406,000,000 US dollars

Medical Surgical

8,417,000,000 US dollars

Diabetes

2,488,000,000 US dollars

Other operating segment

221,000,000 US dollars

Undisclosed (calculated)

1,000,000 US dollars

Research and development expense

2,735,000,000 US dollars

Selling, general, and administrative expense

10,736,000,000 US dollars

Amortization of intangible assets

1,693,000,000 US dollars

Restructuring charges, net

226,000,000 US dollars

Certain litigation charges, net

149,000,000 US dollars

Other operating expense (income), net

464,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

• The amounts that make up operating profit come to $5,145.00 M and operating profit is $5,144.00 M; the $1.00 M difference is within the rounding of the filed amounts.
• The amounts that make up net income come to $3,704.00 M and net income is $3,705.00 M; the $1.00 M difference is within the rounding of the filed amounts.